Replies to post #233365 on Biotech Values

[DewDiligence]

…RVNC—…are the outcomes in line with your expectations for both studies?

Today’s PR doesn’t provide any actual data (which are presumably being held for a medical conference). However, lateral forehead lines and crow’s feet are two areas where botulinum toxin has been widely used, so there is nothing groundbreaking about these two phase-2 trials.

RVNC does not intend to seek regulatory approval for Daxi in lateral forehead lines and crow’s feet. The purpose of these two phase-2 trials was to obtain dosing information to guide injectors who will use Daxi off-label in these indications.